At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 54 enrolled
Drug / intervention
Aspirin +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of Intermittent Versus Continuous Dose Aspirin (ASA) on Nasal Epithelium Gene Expression in Current Smokers
In Brief
A Phase 2 clinical trial evaluating Aspirin, Laboratory Biomarker Analysis, and 1 other intervention for Lung Carcinoma and Tobacco Use Disorder. Completed, enrolled 54 participants across 2 sites.
Detailed Summary
This randomized phase II trial studies the safety and effects of acetylsalicylic acid (aspirin) taken continuously or intermittently on gene expression in the nasal tissue of current smokers. Smokers are at increased risk of developing lung cancer. Acetylsalicylic acid may be useful in preventing lung cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Carcinoma, Tobacco Use Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 2014
Enrollment StartJun 2014
Primary CompletionSep 2016
Study CompletionFeb 2018
TodayJul 2026
First PostedApr 28, 2014
Enrollment StartJun 1, 2014
Primary CompletionSep 1, 2016
Study CompletionFeb 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 12.2 years ago
Interventions
Aspirindrug
Given PO
Laboratory Biomarker Analysisother
Correlative studies
Placeboother
Given PO